Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Revenue Collapse • Rising Leverage • Cash Burn ARWR's revenue collapse, steep losses, negative cash flow, and rising leverage materially weaken its investment outlook despite investment-backed liquidity.
Price Behavior
Key Price Behavior Insights: • Sharp monthly decline • Oversold rebound attempt • Key support test Support Level: $65.79 Resistance Level: $70.67; $80.67–$82.85 ARWR remains bearish over the last month, with oversold momentum hinting at a possible bounce, but a break below $65.79 would increase downside risk unless it reclaims $70.67.
Sentiment & News
Key News Insights: • Phase 3 success • Pipeline expansion • Institutional buying Arrowhead's positive Phase 3 plozasiran results and early ARO-DIMER-PA data strengthen its cardiovascular pipeline outlook despite insider selling.
AI Summary
ARWR is now a commercial-execution story: SHASTA strengthens plozasiran's severe-hypertriglyceridemia expansion potential, but investors should require evidence of a timely filing, broad label, reimbursement, and accelerating sales before overlooking heavy cash burn and leverage.
Description
Arrowhead Pharmaceuticals is a Pasadena-based biopharmaceutical company, founded in 1989, that develops RNA interference therapeutics for a range of liver, cardiovascular, pulmonary, rare genetic and oncology indications. Its clinical-stage pipeline includes candidates targeting liver-expressed proteins, cardiovascular lipid regulators, pulmonary targets and other disease-specific genes, and the company partners with Janssen and Takeda on several liver-directed programs. Arrowhead also participates in collaborations for subcutaneously administered RNAi candidates for chronic hepatitis B and other externally developed programs.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Feb 4 | Feb 11 | ARWR | Arrowhead Pharmaceuticals, Inc. | Arrowhead Pharmaceuticals (ARWR) is a near-term hot idea driven by FDA approval of REDEMPLO®, strong cash runway through 2028, positive clinical pipeline progress, ongoing trials with milestone potential, and robust bullish technical momentum (+12% price rise over three weeks) amidst solid industry sentiment. | Closed | -9.6% |
| Dec 2 | Dec 9 | ARWR | Arrowhead Pharmaceuticals, Inc. | Near-term growth opportunity following FDA approval of REDEMPLO (first siRNA therapy for familial chylomicronemia syndrome), Breakthrough Therapy designation for another indication, $200M Novartis upfront payment, and 32.7% price surge supported by strong technical breakout. | Closed | +18.8% |